open access

Vol 28, No 1 (2022)
Other materials agreed with the Editors
Get Citation

Thrombolytic therapy using recombinant tissue plasminogen activator (r-tPA): the position of the Polish Society for Vascular Surgery

Tomasz Jakimowicz, Zbigniew Krasiński, Maciej Niewada, Grzegorz Borowski, Włodzimierz Hendiger, Arkadiusz Jawień, Tomasz Zubilewicz, Zbigniew Gałązka, Michał Goran Stanisic, Wacław Kuczmik, Stanisław Przywara, Paweł Wierzchowski, Andrzej Wojtak, Piotr Andziak
DOI: 10.5603/AA.2022.0003
·
Acta Angiologica 2022;28(1):1-7.

open access

Vol 28, No 1 (2022)
Requirements

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Thrombolytic therapy using recombinant tissue plasminogen activator (r-tPA): the position of the Polish Society for Vascular Surgery

Journal

Acta Angiologica

Issue

Vol 28, No 1 (2022)

Article type

Other materials agreed with the Editors

Pages

1-7

Page views

169

Article views/downloads

62

DOI

10.5603/AA.2022.0003

Bibliographic record

Acta Angiologica 2022;28(1):1-7.

Authors

Tomasz Jakimowicz
Zbigniew Krasiński
Maciej Niewada
Grzegorz Borowski
Włodzimierz Hendiger
Arkadiusz Jawień
Tomasz Zubilewicz
Zbigniew Gałązka
Michał Goran Stanisic
Wacław Kuczmik
Stanisław Przywara
Paweł Wierzchowski
Andrzej Wojtak
Piotr Andziak

References (25)
  1. Jaff MR, White CJ, Hiatt WR, et al. TASC Steering Committee, TASC Steering Committee, TASC II Working Group, TASC II Working Group, TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007; 33 Suppl 1(2): S1–75.
  2. Patel NH, Krishnamurthy VN, Kim S, et al. CIRSE and SIR Standards of Practice Committees. Quality improvement guidelines for percutaneous management of acute lower-extremity ischemia. J Vasc Interv Radiol. 2013; 24(1): 3–15.
  3. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017; 135(12): e726–e779.
  4. Fluck F, Augustin AM, Bley T, et al. Current Treatment Options in Acute Limb Ischemia. Rofo. 2020; 192(4): 319–326.
  5. Gloviczki P. Choroby żył i układu limfatycznego. Medipage, Warszawa 2020.
  6. Marquis-Gravel G, Tremblay-Gravel M, Lévesque J, et al. Ultrasound guidance versus anatomical landmark approach for femoral artery access in coronary angiography: A randomized controlled trial and a meta-analysis. Journal of Interventional Cardiology. 2018; 31(4): 496–503.
  7. Thrombolysis in the management of lower limb peripheral arterial occlusion, a consensus document. J Vasc Interv Radiol 2003;14:S337e49.
  8. Comerota AJ, Weaver FA, Hosking JD, et al. Results of a prospective, randomized trial of surgery versus thrombolysis for occluded lower extremity bypass grafts. Am J Surg. 1996; 172(2): 105–112.
  9. Jongkind V, Earnshaw JJ, Bastos Gonçalves F, et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia. Eur J Vasc Endovasc Surg. 2020; 59(2): 173–218.
  10. Actylise. Summary of Product Characteristics. https://www.boehringer- ingelheim.pl/sites/pl/files/documents/poland_pdf/actilyse_20_chpl2019.pdf (15.10.2020).
  11. Acheampong P, Ford GA. Pharmacokinetics of alteplase in the treatment of ischaemic stroke. Expert Opin Drug Metab Toxicol. 2012; 8(2): 271–281.
  12. Tanswell P, Seifried E, Su PC, et al. Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. Clin Pharmacol Ther. 1989; 46(2): 155–162.
  13. Verstraete M, Bounameaux H, de Cock F, et al. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther. 1985; 235(2): 506–512.
  14. Nilsson T, Wallén P, Mellbring G. In vivo metabolism of human tissue-type plasminogen activator. Scand J Haematol. 1984; 33(1): 49–53.
  15. Kane I, Sandercock P. Alteplase: thrombolysis for acute ischemic stroke. Therapy. 2005; 2(5): 709–716.
  16. Tanswell P, Seifried E, Stang E, et al. [Recombinant tissue-type plasminogen activator: pharmacokinetics and effect on the hemostasis system of the human]. Klin Wochenschr. 1988; 66 Suppl 12(3): 40–49.
  17. Romeo F, Rosano GM, Martuscelli E, et al. Concurrent nitroglycerin administration reduces the efficacy of recombinant tissue-type plasminogen activator in patients with acute anterior wall myocardial infarction. Am Heart J. 1995; 130(4): 692–697.
  18. Ebben HP, Jongkind V, Wisselink W, et al. Catheter Directed Thrombolysis Protocols for Peripheral Arterial Occlusions: a Systematic Review. Eur J Vasc Endovasc Surg. 2019; 57(5): 667–675.
  19. Giannakakis S, Galyfos G, Sachmpazidis I, et al. Thrombolysis in peripheral artery disease. Ther Adv Cardiovasc Dis. 2017; 11(4): 125–132.
  20. Grip O, Kuoppala M, Acosta S, et al. Outcome and complications after intra-arterial thrombolysis for lower limb ischaemia with or without continuous heparin infusion. Br J Surg. 2014; 101(9): 1105–1112.
  21. Karnabatidis D, Spiliopoulos S, Tsetis D, et al. Quality improvement guidelines for percutaneous catheter-directed intra-arterial thrombolysis and mechanical thrombectomy for acute lower-limb ischemia. Cardiovasc Intervent Radiol. 2011; 34(6): 1123–1136.
  22. Kessel DO, Berridge DC, Robertson I. Infusion techniques for peripheral arterial thrombolysis. Cochrane Database Syst Rev. 2004(1): CD000985.
  23. Hage AN, McDevitt JL, Chick JF, et al. Acute Limb Ischemia Therapies: When and How to Treat Endovascularly. Semin Intervent Radiol. 2018; 35(5): 453–460.
  24. Valle JA, Waldo SW. Current Endovascular Management of Acute Limb Ischemia. Interv Cardiol Clin. 2017; 6(2): 189–196.
  25. Ebben H, Jongkind V, Wisselink W, et al. Catheter Directed Thrombolysis Protocols for Peripheral Arterial Occlusions: a Systematic Review. European Journal of Vascular and Endovascular Surgery. 2019; 57(5): 667–675.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl